Research progress of novel tyrosine kinase inhibitor AC220 in the treatment of acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2015.02.016
- VernacularTitle:新型酪氨酸激酶抑制剂AC220治疗急性髓系白血病的研究进展
- Author:
Li GE
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
FLT3 mutations;
Inhibitors of FLT3;
AC220
- From:
Journal of Leukemia & Lymphoma
2015;24(2):125-128
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is a highly heterogenous disease with multiple signaling pathways contributing to its pathogenesis.A key driver of AML is the mutation of FMS-like tyrosine kinase receptor-3 (FLT3) gene.Mutations in FLT3,primarily the FLT3-internal tandem duplication (FLT3-ITD),are associated with decreased progression-free and overall survival.Due to the importance of FLT3-ITD and its pathway in the prognosis of patients with AML,it has stimulated efforts to develop therapeutic inhibitors of FLT3.Although the FLT3 inhibitors show a certain degree of antileukemia activity,their clinical effect has some limitations as a single drug.Now,Quizartinib (AC220) is the potent second generation FLT3 selective inhibitors.Based on the resistance mechanism for FLT3 inhibitom,more and more scholars has been studying the inhibition of FLT3-ITD+ cell lines and primary leukemia cells by AC220 alone and in combination with cytotoxic chemotherapies/protein kinase inhibitors as well.However,the clinical effects of a variety of combination plan remain to be further investigated.
